1190363-91-7 Usage
Uses
Used in Pharmaceutical Research and Development:
4-nitrophenyl 4-(2,3-dihydro-2-oxoimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate is used as a research compound for its potential pharmacological activities. Its unique structure may contribute to the development of new drugs targeting various therapeutic areas.
Used in Organic Synthesis:
In the field of organic synthesis, 4-nitrophenyl 4-(2,3-dihydro-2-oxoimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate is used as a building block for constructing more complex molecules. Its properties and reactivity can be leveraged to create novel compounds with specific functions and applications.
Further research is necessary to fully understand the potential uses and properties of 4-nitrophenyl 4-(2,3-dihydro-2-oxoimidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate, as its current applications are based on its unique structure and potential.
Check Digit Verification of cas no
The CAS Registry Mumber 1190363-91-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,0,3,6 and 3 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1190363-91:
(9*1)+(8*1)+(7*9)+(6*0)+(5*3)+(4*6)+(3*3)+(2*9)+(1*1)=147
147 % 10 = 7
So 1190363-91-7 is a valid CAS Registry Number.
1190363-91-7Relevant articles and documents
Calcitonin gene-related peptide (CGRP) receptor antagonists: Pyridine as a replacement for a core amide group
Luo, Guanglin,Chen, Ling,Civiello, Rita,Pin, Sokhom S.,Xu, Cen,Kostich, Walter,Kelley, Michelle,Conway, Charles M.,MacOr, John E.,Dubowchik, Gene M.
scheme or table, p. 2917 - 2921 (2012/06/04)
In our continuing efforts to identify CGRP receptor antagonists that can be dosed orally for the treatment of migraine headache, we have investigated a pyridine bioisosteric replacement of a polar amide portion of a previous lead compound, BMS-694153. Pyr
CGRP Receptor Antagonists
-
Page/Page column 46-47, (2009/10/21)
The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).